OTCMKTS:BCTXF

BriaCell Therapeutics Competitors

Add
Compare
Today's Range N/A
50-Day Range
$3.88
MA: $5.30
$6.17
52-Week Range N/A
Volume2,000 shs
Average Volume1,859 shs
Market Capitalization$4.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14

Competitors

BriaCell Therapeutics (OTCMKTS:BCTXF) Vs. BLCM, NTN, SNOA, XTLB, ELDN, and NVUS

Should you be buying BCTXF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BriaCell Therapeutics, including Bellicum Pharmaceuticals (BLCM), NTN Buzztime (NTN), Sonoma Pharmaceuticals (SNOA), XTL Biopharmaceuticals (XTLB), Eledon Pharmaceuticals (ELDN), and Novus Therapeutics (NVUS).

Bellicum Pharmaceuticals (NASDAQ:BLCM) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Bellicum Pharmaceuticals has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Bellicum Pharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bellicum Pharmaceuticals$7.14 million2.49$-112,480,000.00($19.91)-0.18
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

BriaCell Therapeutics has lower revenue, but higher earnings than Bellicum Pharmaceuticals.

Institutional and Insider Ownership

20.2% of Bellicum Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 3.8% of Bellicum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Bellicum Pharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bellicum PharmaceuticalsN/AN/A-26.04%
BriaCell TherapeuticsN/AN/A-786.77%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bellicum Pharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bellicum Pharmaceuticals02002.00
BriaCell Therapeutics0000N/A

Bellicum Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 28.21%.

Summary

Bellicum Pharmaceuticals beats BriaCell Therapeutics on 5 of the 7 factors compared between the two stocks.

NTN Buzztime (NYSEAMERICAN:NTN) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap consumer discretionary companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

NTN Buzztime has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares NTN Buzztime and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NTN Buzztime$19.81 million0.89$-2,050,000.00N/AN/A
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

NTN Buzztime has higher revenue and earnings than BriaCell Therapeutics.

Institutional and Insider Ownership

6.3% of NTN Buzztime shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 24.2% of NTN Buzztime shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NTN Buzztime and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NTN Buzztime-61.42%-162.54%-49.94%
BriaCell TherapeuticsN/AN/A-786.77%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NTN Buzztime and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NTN Buzztime0000N/A
BriaCell Therapeutics0000N/A

Summary

NTN Buzztime beats BriaCell Therapeutics on 5 of the 9 factors compared between the two stocks.

Sonoma Pharmaceuticals (NASDAQ:SNOA) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Sonoma Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sonoma Pharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$18.94 million0.91$-2,950,000.00N/AN/A
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

Sonoma Pharmaceuticals has higher revenue and earnings than BriaCell Therapeutics.

Institutional and Insider Ownership

9.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. 5.6% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sonoma Pharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sonoma Pharmaceuticals-6.04%-29.78%-18.65%
BriaCell TherapeuticsN/AN/A-786.77%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sonoma Pharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sonoma Pharmaceuticals0000N/A
BriaCell Therapeutics0000N/A

Summary

Sonoma Pharmaceuticals beats BriaCell Therapeutics on 5 of the 9 factors compared between the two stocks.

XTL Biopharmaceuticals (NASDAQ:XTLB) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares XTL Biopharmaceuticals and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XTL BiopharmaceuticalsN/A-38.54%-37.40%
BriaCell TherapeuticsN/AN/A-786.77%

Institutional and Insider Ownership

8.6% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

XTL Biopharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for XTL Biopharmaceuticals and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XTL Biopharmaceuticals0000N/A
BriaCell Therapeutics0000N/A

Valuation & Earnings

This table compares XTL Biopharmaceuticals and BriaCell Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL BiopharmaceuticalsN/AN/A$-1,350,000.00N/AN/A
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A

BriaCell Therapeutics (OTCMKTS:BCTXF) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares BriaCell Therapeutics and Eledon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
Eledon PharmaceuticalsN/A-133.49%-30.52%

Institutional & Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BriaCell Therapeutics and Eledon Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Eledon Pharmaceuticals00303.00

Eledon Pharmaceuticals has a consensus target price of $29.50, indicating a potential upside of 158.09%.

Valuation and Earnings

This table compares BriaCell Therapeutics and Eledon Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
Eledon PharmaceuticalsN/AN/A$-16,010,000.00($21.58)-0.53

BriaCell Therapeutics (OTCMKTS:BCTXF) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares BriaCell Therapeutics and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
Novus TherapeuticsN/A-133.49%-30.52%

Institutional & Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BriaCell Therapeutics and Novus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Novus Therapeutics01102.50

Novus Therapeutics has a consensus target price of $50.75, indicating a potential upside of 344.01%.

Valuation and Earnings

This table compares BriaCell Therapeutics and Novus Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
Novus TherapeuticsN/AN/A$-16,010,000.00($21.58)-0.53


BriaCell Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$3.51flat$17.76 million$7.14 million-0.26
NTN Buzztime logo
NTN
NTN Buzztime
0.4$5.94flat$17.68 million$19.81 million-2.88News Coverage
Gap Up
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$8.31flat$17.26 million$18.94 million-9.34Increase in Short Interest
XTLB
XTL Biopharmaceuticals
0.6$3.24flat$16.65 millionN/A-5.23Decrease in Short Interest
News Coverage
Eledon Pharmaceuticals logo
ELDN
Eledon Pharmaceuticals
1.6$11.43flat$16.41 millionN/A-0.51
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.4$11.43flat$16.41 millionN/A-0.51
NMUS
Nemus Bioscience
0.6$0.12flat$16.20 millionN/A0.00High Trading Volume
Gap Down
Intec Pharma logo
NTEC
Intec Pharma
1.4$4.06flat$14.58 millionN/A-0.57
NVLNF
Novelion Therapeutics
0.6$0.70flat$13.77 million$130.43 million0.00Gap Down
Medicure logo
MCUJF
Medicure
0.6$1.32flat$13.53 million$15.20 million-1.05Decrease in Short Interest
News Coverage
MedAvail logo
MDVL
MedAvail
1.9$13.20flat$13.41 million$1.03 million-3.23Analyst Report
Increase in Short Interest
NRIFF
Nuvo Pharmaceuticals
0.7$1.14flat$13.00 million$52.41 million28.50Gap Up
Teligent logo
TLGT
Teligent
1.2$0.58flat$12.62 million$65.90 million-0.07News Coverage
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08flat$11.99 millionN/A-3.90Decrease in Short Interest
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.67flat$11.46 millionN/A-0.89Increase in Short Interest
Gap Up
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.15flat$11.36 millionN/A0.00
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04flat$10.81 million$7.38 million0.00Gap Down
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12flat$10.76 million$4.08 million-1.28Increase in Short Interest
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.14flat$9.87 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53flat$8.77 millionN/A0.00Gap Down
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00Decrease in Short Interest
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00News Coverage
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.32flat$7.07 million$2.66 million-10.67Gap Up
Bioxytran logo
BIXT
Bioxytran
0.0$0.07flat$7.05 millionN/A0.00Gap Up
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06flat$6.39 million$30,000.000.00
KAYS
Kaya
0.7$0.43flat$6.23 million$1.01 million0.00Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23flat$5.46 million$3.48 million-1.92News Coverage
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72flat$5.43 million$9.47 million0.00
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11flat$4.38 million$3.65 million0.00Decrease in Short Interest
Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$4.05 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Increase in Short Interest
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17flat$3.47 millionN/A0.00High Trading Volume
Increase in Short Interest
Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.84 millionN/A-0.09
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.31 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.16 million$20,000.00-0.97News Coverage
Gap Up
IMUCD
ImmunoCellular Therapeutics
0.0$0.51flat$2.14 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00News Coverage
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51flat$1.80 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.70 million$530,000.000.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.52 millionN/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.